Clinical Trial Update: Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of golidocitinib and benmelstobart in relapsed/refractory extranodal natural killer/T-cell lymphoma (nasal ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• Benmelstobart
• Golidocitinib (golidocitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Natural Killer T-cell Lymphoma | Phase 2 | Status: RECRUITING